These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33787591)

  • 41. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI
    Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of inhibitors of factor Xa for the treatment of pulmonary embolism.
    Prandoni P; Temraz S; Barbar S; Pesavento R; Taher A
    Intern Emerg Med; 2014 Sep; 9(6):617-22. PubMed ID: 24871638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
    Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
    Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report.
    Zhou H; Wei Q; Wu H; Tang M; Yang S; Liu Y; Qin L
    Medicine (Baltimore); 2019 May; 98(20):e15705. PubMed ID: 31096518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rivaroxaban for treatment of venous thromboembolism in older adults.
    Mitchell AP; Conway SE
    Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
    Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
    Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Best evidence topic reports. BET 1: is long-term Rivaroxaban superior to Warfarin in pulmonary embolism?
    Morgan C; Body R
    Emerg Med J; 2015 Nov; 32(11):895-8. PubMed ID: 26490283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivaroxaban for Treatment of Pulmonary Embolism While Receiving Electroconvulsive Therapy.
    Shao E; Moore R; Linnane J
    J ECT; 2017 Sep; 33(3):e25-e26. PubMed ID: 28198719
    [No Abstract]   [Full Text] [Related]  

  • 52. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
    Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Possible Rivaroxaban Failure during the Postpartum Period.
    Rudd KM; Winans AR; Panneerselvam N
    Pharmacotherapy; 2015 Nov; 35(11):e164-8. PubMed ID: 26598101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
    van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
    Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
    Wang Y; Wang C; Chen Z; Zhang J; Liu Z; Jin B; Ying K; Liu C; Shao Y; Jing Z; Meng IL; Prins MH; Pap AF; Müller K; Lensing AW;
    Thromb J; 2013 Dec; 11(1):25. PubMed ID: 24341332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.
    Lim MS; Nandurkar D; Jong I; Cummins A; Tran H; Chunilal S
    J Thromb Thrombolysis; 2020 Feb; 49(2):220-227. PubMed ID: 31493288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge.
    Sharifi M; Bay C; Schwartz F; Skrocki L
    Clin Cardiol; 2014 Feb; 37(2):78-82. PubMed ID: 24122947
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivaroxaban plus Percutaneous catheter-directed treatment for a patient with massive pulmonary embolism and colporrhagia.
    Wang W
    Am J Emerg Med; 2018 Aug; 36(8):1522.e5-1522.e7. PubMed ID: 29709396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
    Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
    Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.